Invesaro

Stocks Health care ICCM

NASDAQ · Health care

IceCure Medical Ltd. (ICCM)

IceCure Medical Ltd. reported revenue of $3.4M in fiscal 2025, up 2.7% from a year earlier. It posted a net loss of $15.1M. In fiscal 2025 capital spending exceeded operating cash flow by $14.6M. At December 31, 2025 it held $8.9M in cash against $13K of debt. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on March 17, 2026.

Watch ICCM in 60 seconds
Price
$1.73
-0.58% on the day · September 25, 2026
52-week range $1.65 to $42.00
Market cap
$5.9M
Revenue (FY2025)
$3.4M
+2.7% year on year
Net margin
-445.6%

What IceCure Medical Ltd. does

IceCure Medical Ltd. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker ICCM.

Revenue and profit by year

Revenue
FY19: $1.6M $1.6M FY19FY21: $3.9M $3.9M FY21FY21: $4.1M $4.1M FY21FY22: $3.1M $3.1M FY22FY23: $3.2M $3.2M FY23FY24: $3.3M $3.3M FY24FY25: $3.4M $3.4M FY25
Net income
FY19: -$4.6M -$4.6M FY19FY21: -$3.7M -$3.7M FY21FY21: -$9.9M -$9.9M FY21FY22: -$17M -$17M FY22FY23: -$14.7M -$14.7M FY23FY24: -$15.3M -$15.3M FY24FY25: -$15.1M -$15.1M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$3.4M-$15.1M-$15.1M$0.24-$14.6M
2024$3.3M-$15.7M-$15.3M$0.30-$12.6M
2023$3.2M-$15.6M-$14.7M$0.32-$13M
2022$3.1M-$16.7M-$17M$0.46-$15.2M
2021$4.1M-$9.7M-$9.9M$0.35-$13.1M
2021$3.9M-$4.1M-$3.7M$0.22-$3.9M

Full financial statements: income, balance sheet and cash flow

Where ICCM ranks in Health care

Revenue$3.4M
#526 of 646 in Health care · Bottom 19%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What IceCure Medical Ltd. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 10, 2026
  2. August 24, 2026
  3. August 14, 2026
  4. August 14, 2026
  5. August 14, 2026
  6. August 13, 2026
  7. August 13, 2026
  8. August 12, 2026
  9. August 11, 2026
  10. August 6, 2026

Recent insider filings (Forms 3, 4 and 144): 10, the latest on August 17, 2026. Insider transactions on SEC

Insider trades

What the people running IceCure Medical Ltd. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider bought or sold shares on the open market in the last 90 days. The 5 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.

Bought (open market)
$0
last 90 days
Sold
$0
last 90 days
DateInsiderWhatSharesPriceValueFiling
August 14, 2026 Peleg MeirChief Financial Officer Received as pay 181,483 - - Form 4
August 14, 2026 Dotan Merav NirVP, Human Resources Received as pay 73,890 - - Form 4
August 14, 2026 Levav ShayChief Operating Officer Received as pay 141,483 - - Form 4
August 14, 2026 Tel-Tzure Tlalit BussiVP, BD & Global Marketing Received as pay 101,483 - - Form 4
August 14, 2026 Good ShadVP, Sales for North America Received as pay 131,483 - - Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns ICCM

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

HolderOf classSharesFiled
Mr. Li Haixiang13D, may seek influence with 1 related filers 45.8% 35,846,597 March 27, 2026
Armistice Capital, LLC13G, passive with 1 related filers 9.99% 300,332 August 14, 2026

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

5 insiders reported holding 660,503 shares in total, about $1.1M at the last price.

HolderSharesAs of
Peleg MeirChief Financial Officer 194,816 August 14, 2026
Levav ShayChief Operating Officer 146,303 August 14, 2026
Good ShadVP, Sales for North America 136,698 August 14, 2026
Tel-Tzure Tlalit BussiVP, BD & Global Marketing 106,518 August 14, 2026
Dotan Merav NirVP, Human Resources 76,168 August 14, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about ICCM

What does IceCure Medical Ltd. do?

IceCure Medical Ltd. is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NASDAQ under the ticker ICCM.

Is IceCure Medical Ltd. profitable?

No. In fiscal 2025 it reported a net loss of $15.1M on revenue of $3.4M.

How much revenue does IceCure Medical Ltd. make?

In fiscal 2025 IceCure Medical Ltd. reported revenue of $3.4M. That is 2.7% more than a year earlier.

When did IceCure Medical Ltd. last report?

Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on March 17, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from September 10, 2026.

Similar companies

Compare ICCM with

Compare ICCM with any company

Follow ICCM

Get an email when IceCure Medical Ltd. files with the SEC: results, executive changes, material agreements and annual reports.

Follow ICCM: get an email when it files

Where the numbers come from

Financial figures are the values IceCure Medical Ltd. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.